Europe Neuropathic Pain Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 1,123.93 million |
 Taille du marché (année de prévision) |
USD 2,371.40 million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen de la douleur neuropathique, par type (dispositifs de stimulation de la moelle épinière (SCS), stimulation nerveuse périphérique externe, dispositifs de stimulation nerveuse électrique transcutanée (Tens)), type de produit (rechargeable et non rechargeable), procédure (invasive et non invasive), technologie (stimulation nerveuse électrique transcutanée, stimulation magnétique transcrânienne et stimulation électrique respiratoire), modalité (fixe et portable), mode d'achat (dispositifs en vente libre et sur ordonnance), type de douleur (neuropathie périphérique, neuropathie par piégeage, neuropathie du membre fantôme, névralgie du trijumeau, névralgie post-herpétique (PHN), neuropathie post-traumatique, douleur au pied, coccydynie), indication (sténose spinale, neuropathie périphérique induite par chimiothérapie, neuropathie diabétique, autres), utilisateur final (hôpitaux, cliniques, soins à domicile, ambulatoires) Centres chirurgicaux et autres, canal de distribution (appel d'offres direct, distributeur tiers et autres) – Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché de la douleur neuropathique en Europe
L'augmentation des dépenses de recherche et développement par divers acteurs du marché pour créer des produits avancés devrait stimuler la croissance du marché européen de la douleur neuropathique. Les limitations associées aux dispositifs médicaux qui limitent l'utilisation des produits devraient freiner la croissance du marché européen de la douleur neuropathique. Le risque élevé de douleur neuropathique lié au vieillissement et à l'augmentation de la population âgée dans de nombreux pays créera une opportunité pour la croissance du marché européen de la douleur neuropathique. Le recours aux thérapies traditionnelles dans les pays émergents en raison des faibles dépenses de santé et de la perturbation de la chaîne d'approvisionnement devrait constituer un défi pour la croissance du marché européen de la douleur neuropathique.
Français Data Bridge Market Research analyse que le marché européen de la douleur neuropathique, qui était de 1 123,93 millions USD en 2022, devrait atteindre 2 371,40 millions USD d'ici 2030 et devrait connaître un TCAC de 9,1 % au cours de la période de prévision de 2023 à 2030. Le segment des « dispositifs de stimulation de la moelle épinière (SCS) » domine le segment type du marché européen de la douleur neuropathique en raison des avancées technologiques. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.
Portée et segmentation du marché européen de la douleur neuropathique
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, volumes en unités, prix en USD |
|
Segments couverts |
Type (dispositifs de stimulation de la moelle épinière (SCS), stimulation nerveuse périphérique externe, dispositifs de stimulation nerveuse électrique transcutanée (Tens)), type de produit (rechargeable et non rechargeable), procédure (invasive et non invasive), technologie (stimulation nerveuse électrique transcutanée, stimulation magnétique transcrânienne et stimulation électrique respiratoire), modalité (fixe et portable), mode d'achat (dispositifs en vente libre et sur ordonnance), type de douleur ( neuropathie périphérique , neuropathie par piégeage, neuropathie du membre fantôme, névralgie du trijumeau, névralgie post-herpétique (PHN), neuropathie post-traumatique, douleur au pied, coccydynie), indication (sténose spinale, neuropathie périphérique induite par chimiothérapie, neuropathie diabétique , autres), utilisateur final (hôpitaux, cliniques, soins à domicile, centres de chirurgie ambulatoire et Autres), canal de distribution (appel d'offres direct, distributeur tiers et autres) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Pays-Bas, Suisse, Belgique, Russie, Italie, Espagne, Turquie, Reste de l'Europe |
|
Acteurs du marché couverts |
NEVRO CORP. (États-Unis), Boston Scientific Corporation (États-Unis), Abbott (États-Unis), electroCore, Inc. (États-Unis), Polar Medical (Angleterre), B. Braun Melsungen AG (Allemagne), Omron Healthcare, Inc. (Japon), Cirtec (États-Unis), Medtronic (Irlande), Pfizer Inc. (États-Unis), Novartis AG (Suisse), Virpax Pharmaceuticals, Inc. (États-Unis), Amgen Inc. (États-Unis), Integer Holdings Corporation (États-Unis) et AVNS (États-Unis) |
|
Opportunités de marché |
|
Définition du marché
La douleur neuropathique est provoquée par une lésion ou une maladie du système somatosensoriel, notamment des fibres périphériques (fibres Aβ, Aδ et C) et des neurones centraux. Elle touche 7 à 10 % de la population générale. De multiples causes de douleur neuropathique ont été décrites et son incidence est susceptible d'augmenter en raison du vieillissement de la population mondiale, de l'incidence accrue du diabète sucré et de l'amélioration de la survie au cancer après chimiothérapie.
Dynamique du marché européen de la douleur neuropathique
Conducteurs
- Prévalence croissante de la douleur neuropathique
À mesure que la population vieillit et que les maladies chroniques telles que le diabète et le cancer deviennent plus fréquentes, le nombre de personnes souffrant de douleurs neuropathiques est en hausse. Cette tendance démographique stimule la demande de traitements et de médicaments contre la douleur neuropathique.
- Progrès de la recherche médicale
Les recherches en cours sur les causes et les mécanismes de la douleur neuropathique ont conduit au développement de nouvelles options de traitement et de thérapies. À mesure que notre compréhension de la douleur neuropathique s'améliore, des traitements plus efficaces sont développés, créant des opportunités pour les sociétés pharmaceutiques et biotechnologiques.
- Développement de nouveaux médicaments
Les sociétés pharmaceutiques investissent dans le développement de nouveaux médicaments spécifiquement conçus pour cibler la douleur neuropathique. Ces médicaments visent à soulager la douleur avec moins d’effets secondaires, améliorant ainsi la qualité de vie des patients.
Opportunités
- Sensibilisation croissante des patients
La prise de conscience croissante de la douleur neuropathique et de son impact sur la vie des patients a entraîné une demande accrue de traitements efficaces. Les patients sont de plus en plus proactifs dans la recherche de soins et de thérapies adaptés.
- Augmentation des dépenses de santé
Alors que les dépenses de santé continuent d’augmenter à l’échelle mondiale, davantage de fonds sont disponibles pour la recherche, le développement et l’accès aux traitements et thérapies contre la douleur neuropathique.
Contraintes/Défis
- Efficacité limitée des traitements actuels
De nombreux médicaments et thérapies contre la douleur neuropathique n'apportent qu'un soulagement partiel et peuvent entraîner des effets secondaires. Cette efficacité limitée peut conduire à l'insatisfaction des patients et à la recherche de traitements alternatifs.
-
Effets secondaires et problèmes de sécurité
Certains médicaments contre la douleur neuropathique, notamment les opioïdes et certains antidépresseurs, peuvent provoquer des effets secondaires tels que somnolence, étourdissements et dépendance. La gestion de ces effets secondaires peut être difficile tant pour les patients que pour les prestataires de soins de santé.
Ce rapport sur le marché européen de la douleur neuropathique fournit des détails sur les nouveaux développements récents, les réglementations commerciales, l'analyse des importations et des exportations, l'analyse de la production, l'optimisation de la chaîne de valeur, la part de marché, l'impact des acteurs du marché national et localisé, les opportunités d'analyse en termes de poches de revenus émergentes, les changements dans la réglementation du marché, l'analyse stratégique de la croissance du marché, la taille du marché, la croissance du marché des catégories, les niches d'application et la domination, les approbations de produits, les lancements de produits, les expansions géographiques, les innovations technologiques sur le marché. Pour obtenir plus d'informations sur le marché européen de la douleur neuropathique, contactez Data Bridge Market Research pour un briefing d'analyste, notre équipe vous aidera à prendre une décision de marché éclairée pour atteindre la croissance du marché.
Développements récents
- En janvier 2023, Abbott a annoncé que la Food and Drug Administration (FDA) américaine avait approuvé son système de stimulation de la moelle épinière (SCS) Proclaim XR pour traiter la neuropathie périphérique diabétique (DPN) douloureuse, une complication débilitante du diabète.
- En juillet 2022, Vertex Pharmaceuticals Incorporated a annoncé des résultats positifs de phase 2 du VX-548 dans le traitement de la douleur aiguë et neuropathique par la Food and Drug Administration (FDA) des États-Unis.
Portée du marché européen de la douleur neuropathique
Le marché européen de la douleur neuropathique est segmenté en fonction du type, du type de produit, de la procédure, de la technologie, de la modalité, du mode d'achat, du type de douleur, de l'indication, de l'utilisateur final et du canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance faibles dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Taper
- Dispositifs de stimulation de la moelle épinière (SCS)
- Stimulation nerveuse périphérique externe
- Appareils de neurostimulation électrique transcutanée (Tens)
Type de produit
- Rechargeable
- Non rechargeable
Procédure
- Envahissant
- Non invasif
Technologie
- Stimulation nerveuse électrique transcutanée
- Stimulation magnétique transcrânienne
- Stimulation électrique respiratoire
Modalité
- Stationnaire
- Portable
Mode of Purchase
- Over-the-Counter Devices
- Prescription-Based Devices
Pain Type
- Peripheral Neuropathy
- Entrapment Neuropathy
- Phantom Limb Neuropathy
- Trigeminal Neuralgia
- Post Herpetic Neuralgia (PHN)
- Post Traumatic Neuropathy
- Foot Pain
- Coccydynia
Indication
- Spinal Stenosis
- Chemotherapy-Induced Peripheral Neuropathy
- Diabetic Neuropathy
- Others
End User
- Hospitals
- Clinics
- Home Healthcare
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct Tender
- Third Party Distributor
- Others
Europe Neuropathic Pain Market Regional Analysis/Insights
The Europe neuropathic pain market is analysed and market size insights and trends are provided by country, type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user, and distribution channel as referenced above.
The countries covered in the Europe neuropathic pain market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and Rest of Europe
Germany dominates the Europe neuropathic pain market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
Germany is expected to witness significant growth in the Europe neuropathic pain market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Europe neuropathic pain market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe neuropathic pain market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe neuropathic pain market. The data is available for historic period 2015-2020.
Competitive Landscape and Europe Neuropathic Pain Market Share Analysis
The Europe neuropathic pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe neuropathic pain market.
Some of the major players operating in the Europe neuropathic pain market are:
- NEVRO CORP. (U.S.)
- Boston Scientific Corporation (U.S.)
- Abbott (U.S.)
- electroCore, Inc. (U.S.)
- Polar Medical (England)
- B. Braun Melsungen AG (Germany)
- Omron Healthcare, Inc. (Japan)
- Cirtec (U.S.)
- Medtronic (Ireland)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Virpax Pharmaceuticals, Inc. (U.S.)
- Amgen Inc.(U.S.)
- Integer Holdings Corporation (U.S.)
- AVNS (U.S.)
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of EUROPE Neuropathic pain MARKET
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- type LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- vendor share analysis
- MARKET type of manufacturer COVERAGE GRID
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insight
- regulation
- REGULATORY GUIDELINES AS PER USFDA
- REGULATORY GUIDELINES AS PER EUROPEAN UNION
- market overview
- drivers
- Growing prevalence of chronic pain and neuropathic condition
- Increasing Cases Of Diabetic Neuropathy
- Increasing R&D Expenditure
- Advancement In New Neuromodulation Technology
- Penetration Of the New Market Players
- RESTRAINTS
- High cost of the medical devices
- Low awareness for neuropathic pain devices
- unfavorable government policies
- Limitation of Neuropathic medical Devices
- OPPORTUNITIES
- High Risk Of Neuropathic Pain With Ageing
- Government initiatives for neuropathic pain
- Appropriate Reimbursement policy for the medical devices
- CHALLENGES
- Dearth of skilled professionals
- Use of traditional therapy in emerging economies
- IMPACT OF COVID-19 ON THE EUROPE NEUROPATHIC PAIN MARKET
- OVERVIEW
- IMPACT ON PRICE
- IMPACT ON SUPPLY
- STRATEGIC DECISIONS BY MANUFACTURERS
- CONCLUSION-
- europe Neuropathic pain MARKET, BY Type
- overview
- SPINAL CORD STIMULATION (SCS) DEVICES
- Rechargeable Implantable Pulse Generator
- Radiofrequency Stimulator
- Conventional Implantable Pulse Generator/ IPG
- EXTERNAL PERIPHERAL NERVE STIMULATION
- Deep Brain Stimulators (DBS)
- Dual-Channel Deep Brain Stimulator
- Single-Channel Deep Brain Stimulator
- Transcranial Magnetic Stimulators (TMS)
- Vagus Nerve Stimulators (VNS)
- Sacral Nerve Stimulators (SNS)
- TRANSCUTANEOUS ELECTRIC NERVE STIMULATION (TENS) DEVICES
- Conventional Tens (Low-intensity, High-Frequency)
- Acupuncture-Like Tens (High-Intensity, Low-Frequency)
- Intense Tens (High-Intensity, High-Frequency)
- europe Neuropathic pain MARKET, BY product type
- overview
- rechargeable
- non- rechargeable
- europe Neuropathic pain MARKET, BY Procedure
- overview
- Non-Invasive
- invasive
- europe Neuropathic pain MARKET, BY technology
- overview
- TRANSCUTANEOUS ELECTRIC NERVE STIMULATION
- TRANSCRANIAL MAGNETIC STIMULATION
- Respiratory Electrical Stimulation
- europe Neuropathic pain MARKET, BY Modality
- overview
- portable
- Rechargeable
- Non- Rechargeable
- stationary
- Rechargeable
- Non- Rechargeable
- europe Neuropathic pain MARKET, BY Mode of Purchase
- overview
- Prescription-Based Devices
- Over-The-Counter Devices
- europe Neuropathic pain MARKET, BY Pain Type
- overview
- Peripheral Neuropathy
- Phantom Limb Pain
- Post Herpetic Neuralgia (PHN)
- Post Traumatic Neuropathy
- Entrapment Neuropathy
- Foot Pain
- Trigeminal Neuralgia
- Coccydynia
- others
- europe Neuropathic pain MARKET, BY indication
- overview
- Spinal Stenosis
- Spinal Cord Stimulation (SCS) Devices
- Transcutaneous Electrical Nerve Stimulation (TENS) devices
- External Peripheral Nerve Stimulation
- Diabetic Neuropathy
- Spinal Cord Stimulation (SCS) Devices
- Transcutaneous Electrical Nerve Stimulation (TENS) devices
- External Peripheral Nerve Stimulation
- Chemotherapy-Induced Peripheral Neuropathy
- Spinal Cord Stimulation (SCS) Devices
- Transcutaneous Electrical Nerve Stimulation (TENS) devices
- External Peripheral Nerve Stimulation
- others
- europe Neuropathic pain MARKET, BY end user
- overview
- Clinics
- Hospitals
- Acute Care Hospitals
- Long-Term Care Hospitals
- Nursing Facilities
- Rehabilitation Centers
- Home Healthcare
- Ambulatory Surgical Centers
- others
- europe Neuropathic pain MARKET, BY distribution channel
- overview
- Direct Tenders
- Third Party Distribution
- others
- Europe neuropathic Pain market by geography
- Overview
- EUROPE
- GERMANY
- france
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Turkey
- Switzerland
- Rest of Europe
- Europe Neuropathic Pain Market: COMPANY landscape
- company share analysis: europe
- swot analysis
- Company profile
- medtronic
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- boston scientific corporation
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ABBOTT
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- nervo corp.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- omron healthcare, INC.
- COMPANY SNAPSHOT
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Interger holdings corporation
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- avns
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- b.braun melsungen AG
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- Cirtec
- 257
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ELECTROCORE, INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Neurometrix, inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Polar medical
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- Spr therapeutics
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Stimwave LLC.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- sunmed
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- questionnaire
- related reports
Liste des tableaux
TABLE 1 Europe Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 2 Europe Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 3 Europe Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 4 Europe External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 5 Europe External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 6 Europe Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 7 Europe Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 8 Europe Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 9 Europe Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 10 Europe Rechargeable in Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 11 Europe Non-Rechargeable Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 12 Europe Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 13 Europe Non-Invasive Invasive in Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 14 Europe Invasive in Neuroendocrine Tumors Market, By Classification 2019-2027 (USD Million)
TABLE 15 Europe Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 16 Europe Transcutaneous Electrical Nerve Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 17 Europe Transcranial Magnetic Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 18 Europe Respiratory Electrical Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 19 Europe Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 20 Europe Portable Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 21 Europe Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 22 Europe Stationary Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 23 Europe Stationary Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 24 Europe Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 25 Europe Prescription-Based Devices Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 26 Europe Over-The-Counter Devices Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 27 Europe Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 28 Europe Peripheral Neuropathy Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 29 Europe Phantom Limb Pain Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 30 Europe Post Herpetic Neuralgia (PHN) Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 31 Europe Post Traumatic NeuropathyNeuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 32 Europe Entrapment Neuropathy Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 33 Europe Foot Pain Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 34 Europe Trigeminal Neuralgia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 35 Europe Coccydynia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 36 Europe Others Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 37 Europe Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 38 Europe Spinal Stenosis Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 39 Europe Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 40 Europe Diabetic Neuropathy Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 41 Europe Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 42 Europe Chemotherapy-Induced Peripheral Neuropathy Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 43 Europe Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 44 Europe Others Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 45 Europe Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 46 Europe Clinics Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 47 Europe Hospitals Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 48 Europe Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 49 Europe Home Healthcare Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 50 Europe Ambulatory Surgical Centers Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 51 Europe Others Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 52 Europe Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 53 Europe Direct Tenders Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 54 Europe Third Party Distribution Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 55 Europe Others Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 56 EUROPE neuropathic Pain MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 57 Europe NEUROPATHIC PAIN MARKET, By Region, 2019-2028 (USD Million)
TABLE 58 EUROPE NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 59 EUROPE Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 60 EUROPE External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 61 EUROPE Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 62 EUROPE Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 63 EUROPE NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 64 EUROPE NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 65 EUROPE NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 66 EUROPE NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 67 EUROPE Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 68 EUROPE portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 69 EUROPE NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 70 EUROPE NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 71 EUROPE NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 72 EUROPE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 73 EUROPE Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 74 EUROPE Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 75 EUROPE NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 76 EUROPE hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 77 EUROPE NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 78 GERMANY NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 79 GERMANY Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 80 GERMANY External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 81 germany Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 82 GERMANY Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 83 GERMANY NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 84 GERMANY NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 85 GERMANY NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 86 GERMANY NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 87 GERMANY Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 88 GERMANY portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 89 GERMANY NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 90 GERMANY NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 91 GERMANY NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 92 GERMANY SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 93 GERMANY Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 94 GERMANY Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 95 GERMANY NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 96 GERMANY hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 97 GERMANY NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 98 france NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 99 france Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 100 france External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 101 france Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 102 france Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 103 france NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 104 france NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 105 france NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 106 france NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 107 france Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 108 france portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 109 france NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 110 france NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 111 france NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 112 france SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 113 france Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 114 france Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 115 france NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 116 france hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 117 france NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 118 U.K. NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 119 U.K. Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 120 U.K. External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 121 U.K. Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 122 U.K. Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 123 U.K. NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 124 U.K. NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 125 U.K. NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 126 U.K. NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 127 U.K. Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 128 U.K. portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 129 U.K. NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 130 U.K. NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 131 U.K. NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 132 U.K. SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 133 U.K. Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 134 U.K. Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 135 U.K. NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 136 U.K. hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 137 U.K. NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 138 italy NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 139 italy Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 140 italy External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 141 italy Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 142 italy Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 143 italy NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 144 italy NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 145 italy NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 146 italy NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 147 italy Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 148 italy portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 149 italy NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 150 italy NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 151 italy NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 152 italy SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 153 italy Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 154 italy Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 155 italy NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 156 italy hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 157 italy NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 158 russia NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 159 russia Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 160 russia External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 161 russia Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 162 russia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 163 russia NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 164 russia NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 165 russia NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 166 russia NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 167 russia Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 168 russia portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 169 russia NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 170 russia NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 171 russia NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 172 russia SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 173 russia Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 174 russia Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 175 russia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 176 russia hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 177 russia NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 178 spain NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 179 spain Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 180 spain External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 181 spain Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 182 spain Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 183 spain NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 184 spain NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 185 spain NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 186 spain NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 187 spain Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 188 spain portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 189 spain NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 190 spain NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 191 spain NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 192 spain SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 193 spain Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 194 spain Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 195 russia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 196 spain hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 197 spain NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 198 Netherlands NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 199 Netherlands Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 200 Netherlands External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 201 Netherlands Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 202 Netherlands Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 203 Netherlands NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 204 Netherlands NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 205 Netherlands NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 206 Netherlands NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 207 Netherlands Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 208 Netherlands portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 209 Netherlands NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 210 Netherlands NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 211 Netherlands NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 212 Netherlands SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 213 Netherlands Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 214 Netherlands Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 215 Netherlands NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 216 Netherlands hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 217 Netherlands NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 218 turkey NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 219 turkey Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 220 turkey External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 221 turkey Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 222 turkey Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 223 turkey NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 224 turkey NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 225 turkey NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 226 turkey NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 227 turkey Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 228 turkey portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 229 turkey NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 230 turkey NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 231 turkey NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 232 turkey SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 233 turkey Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 234 turkey Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 235 turkey NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 236 turkey hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 237 turkey NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 238 Switzerland NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 239 Switzerland Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 240 Switzerland External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 241 Switzerland Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 242 Switzerland Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 243 Switzerland NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 244 Switzerland NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 245 Switzerland NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 246 Switzerland NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 247 Switzerland Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 248 Switzerland portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 249 Switzerland NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 250 Switzerland NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 251 Switzerland NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 252 Switzerland SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 253 Switzerland Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 254 Switzerland Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 255 Switzerland NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 256 Switzerland hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 257 Switzerland NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 258 Rest of Europe NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
Liste des figures
FIGURE 1 Europe NEUROPATHIC PAIN MARKET: SEGMENTATION
FIGURE 2 EUROPE NEUROPATHIC PAIN MARKET: DATA TRIANGULATION
FIGURE 3 europe Neuropathic pain Market: DROC ANALYSIS
FIGURE 4 Europe Neuropathic pain market: Europe VS REGIONAL MARKET ANALYSIS
FIGURE 5 Europe Neuropathic pain Market: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE Neuropathic pain MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE Neuropathic pain MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE NEUROPATHIC PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE NEUROPATHIC PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE Neuropathic pain MARKET: MARKET type COVERAGE GRID
FIGURE 11 Europe Neuropathic pain market: SEGMENTATION
FIGURE 12 NORTH AMERICA is expected to DOMINATE THE EUROPE Neuropathic pain market AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 GROWING PREVALENCE OF CHRONIC PAIN, NEUROPATHIC CONDITION, AND INCREASING CASES OF DIABETIC NEUROPATHY IS DRIVING THE EUROPE NEUROPATHIC PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 SPINAL CORD STIMULATION (SCS) DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NEUROPATHIC PAIN MARKET IN 2021 & 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE NEUROPATHIC PAIN MARKET
FIGURE 16 ESTIMATED CASES OF PERIPHERAL NEUROPATHY IN AMERICAN POPULATION
FIGURE 17 PREVALENCE OF NEUROPATHIC PAIN IN TYPE 1 AND TYPE 2 DIABETES
FIGURE 18 europe Neuropathic pain market: BY type, 2020
FIGURE 19 europe Neuropathic pain market: BY type, 2020-2028 (USD Million)
FIGURE 20 europe Neuropathic pain market: BY type, CAGR (2020-2028)
FIGURE 21 europe Neuropathic pain market: BY type, LIFELINE CURVE
FIGURE 22 europe Neuropathic pain market: BY product type, 2020
FIGURE 23 europe Neuropathic pain market: BY product type, 2020-2028 (USD Million)
FIGURE 24 europe Neuropathic pain market: BY product type, CAGR (2020-2028)
FIGURE 25 europe Neuropathic pain market: BY product type, LIFELINE CURVE
FIGURE 26 europe Neuropathic pain market: BY procedure, 2020
FIGURE 27 europe Neuropathic pain market: BY procedure, 2020-2028 (USD Million)
FIGURE 28 europe Neuropathic pain market: BY procedure, CAGR (2020-2028)
FIGURE 29 europe Neuropathic pain market: BY procedure, LIFELINE CURVE
FIGURE 30 europe Neuropathic pain market: BY technology, 2020
FIGURE 31 europe Neuropathic pain market: BY technology, 2020-2028 (USD Million)
FIGURE 32 europe Neuropathic pain market: BY technology, CAGR (2020-2028)
FIGURE 33 europe Neuropathic pain market: BY technology, LIFELINE CURVE
FIGURE 34 europe Neuropathic pain market: BY modality, 2020
FIGURE 35 europe Neuropathic pain market: BY modality, 2020-2028 (USD Million)
FIGURE 36 europe Neuropathic pain market: BY modality, CAGR (2020-2028)
FIGURE 37 europe Neuropathic pain market: BY modality, LIFELINE CURVE
FIGURE 38 europe Neuropathic pain market: BY mode of purchase, 2020
FIGURE 39 europe Neuropathic pain market: BY mode of purchase, 2020-2028 (USD Million)
FIGURE 40 europe Neuropathic pain market: BY mode of purchase, CAGR (2020-2028)
FIGURE 41 europe Neuropathic pain market: BY mode of purchase, LIFELINE CURVE
FIGURE 42 europe Neuropathic pain market: BY pain type, 2020
FIGURE 43 europe Neuropathic pain market: BY pain type, 2020-2028 (USD Million)
FIGURE 44 europe Neuropathic pain market: BY pain type, CAGR (2020-2028)
FIGURE 45 europe Neuropathic pain market: BY pain type, LIFELINE CURVE
FIGURE 46 europe Neuropathic pain market: BY indication, 2020
FIGURE 47 europe Neuropathic pain market: BY indication, 2020-2028 (USD Million)
FIGURE 48 europe Neuropathic pain market: BY indication, CAGR (2020-2028)
FIGURE 49 europe Neuropathic pain market: BY indication, LIFELINE CURVE
FIGURE 50 europe Neuropathic pain market: BY end user, 2020
FIGURE 51 europe Neuropathic pain market: BY end user, 2020-2028 (USD Million)
FIGURE 52 europe Neuropathic pain market: BY end user, CAGR (2020-2028)
FIGURE 53 europe Neuropathic pain market: BY end user, LIFELINE CURVE
FIGURE 54 europe Neuropathic pain market: BY distribution channel, 2020
FIGURE 55 europe Neuropathic pain market: BY distribution channel, 2020-2028 (USD Million)
FIGURE 56 europe Neuropathic pain market: BY distribution channel, CAGR (2020-2028)
FIGURE 57 europe Neuropathic pain market: BY distribution channel, LIFELINE CURVE
FIGURE 58 EUROPE neuropathic Pain market: SNAPSHOT (2020)
FIGURE 59 EUROPE neuropathic Pain market: BY COUNTRY (2020)
FIGURE 60 EUROPE neuropathic Pain market: BY COUNTRY (2021 & 2028)
FIGURE 61 EUROPE neuropathic Pain market: BY COUNTRY (2020 & 2028)
FIGURE 62 EUROPE neuropathic Pain market: BY Product & services (2021-2028)
FIGURE 63 Europe Neuropathic Pain MARKET: SNAPSHOT (2020)
FIGURE 64 Europe Neuropathic Pain MARKET: BY COUNTRY (2020)
FIGURE 65 Europe Neuropathic Pain MARKET: BY COUNTRY (2021 & 2028)
FIGURE 66 Europe Neuropathic Pain MARKET: BY COUNTRY (2020 & 2028)
FIGURE 67 Europe Neuropathic Pain MARKET: BY product & Services (2021-2028)
FIGURE 68 Europe Neuropathic Pain market: company share 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
